Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
Jörge E. Cortes(Augusta University Health), Mark J. Levis(Sidney Kimmel Cancer Center), Pau Montesinos(Instituto de Salud Carlos III), Siddhartha Ganguly(University of Kansas Medical Center), Antoine Yver(Daiichi Sankyo (United States)), Melissa F. Holmes(Daiichi Sankyo (United States)), Markus P. Radsak(Johannes Gutenberg University Mainz), Nigel H. Russell(Guy's and St Thomas' NHS Foundation Trust), Alexander E. Perl(University of Pennsylvania), Yufen Zhang(Daiichi Sankyo (United States)), Priyanka Mehta, Ruth Namuyinga(Daiichi Sankyo (United States)), Brian A. Jonas(Cellular Therapeutics (United Kingdom)), Donna E. Hogge(University of British Columbia), Simona Sica(San Antonio College), Giovanni Martinelli(University of Bologna), Samer K. Khaled, Ken Kobayashi(Tokyo Women's Medical University), Anskar Y.H. Leung(Chinese University of Hong Kong), Meena Arunachalam(Daiichi Sankyo (United States)), Hervé Dombret(University of London Institute in Paris), Alwin Krämer(Heidelberg University), Nanxiang Ge(Daiichi Sankyo (United States))
Cited by 486
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k